However, clinical trial data in B-cell lymphoma are limited, and the low efficacy of venetoclax as a single agent in DLBCL and other B-cell lymphomas suggests that lymphoma cells are mostly resistant to BCL2 inhibition alone [20]. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.